等待开盘 08-01 09:30:00 美东时间
-0.070
-2.52%
Evaxion A/S will present two-year clinical data from its phase 2 trial for EVX-01, a personalized cancer vaccine for advanced melanoma, at the 2025 ESMO Congress in Berlin. EVX-01, developed using Evaxion's AI-Immunology™ platform, has shown promising results in early trials, including a 69% Overall Response Rate and tumor reduction in 15 out of 16 patients. The presentation will highlight long-term efficacy and immune response data. The phase 2 ...
07-25 13:00
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion's €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth of ordinary Evaxion
07-11 20:07
Christian Kanstrup has stepped down as CEO of Evaxion A/S. Dr. Birgitte Rønø, the Chief Scientific Officer, has been appointed interim CEO, and the search for a new permanent CEO has begun. Additionally, Thomas Schmidt has been named permanent Chief Financial Officer. The company aims to optimize the value of its AI-Immunology™ platform under these leadership changes.
07-01 12:30
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock moved upwards by 19.6% to $0...
06-26 05:06
Initial computational analysis demonstrated that Evaxion's AI-Immunology™ platform can identify novel vaccine targets to combat Group A Streptococcus (GAS)New vaccine program is added to Evaxion's pipeline under
06-25 20:15
Evaxion A/S has initiated a new vaccine program, EVX-B4, to combat Group A Streptococcus (GAS), a bacteria causing millions of infections globally. Using its AI-Immunology™ platform, the company aims to identify novel vaccine targets, addressing the urgent need for preventive measures against GAS infections, which can lead to severe complications like rheumatic heart disease and necrotizing fasciitis. EVX-B4 aligns with Evaxion’s strategy to part...
06-25 12:00
整体来看,今年上榜的500位企业家(或家族)总持股市值为13.7万亿元,同比上涨11%,平均持股市值为273.8亿元,上榜门槛为66.2亿元,持股市值百亿以上的企业家达341位。
06-24 15:51
Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicating polio, a highly infectious viral diseaseEvaxion will apply its leading AI-Immunology™ platform to identify and
06-03 21:19
Evaxion awarded a Gates Foundation grant to develop a new polio vaccine using its AI-Immunology™ platform. The project aims to identify and combine antigens to design novel vaccine constructs, eliminating the need for live viruses. With polio risks persisting, this breakthrough approach could help achieve global eradication.
06-03 13:15